Tests a T-cell and B-cell removal method in blood cancer stem cell transplants

Who can take part

• Patient age < 25 years. Both genders and all races eligible
• Disease eligibility; Acute myeloid leukemia, primary or secondary - Disease status: MRD negative (flow MRD ≤ 0.1%); Myelodysplasia; Acute lymphoblastic leukemia - Disease status: MRD negative; Chronic myelogenous leukemia - Disease status: chronic phase, accelerated phase or blast crisis now in second chronic phase; Mixed lineage or biphenotypic acute leukemia- Disease status: MRD negative; Lymphoblastic lymphoma - Disease status: in remission; Burkitt's lymphoma/leukemia - Disease status: in remission; Lymphoma after relapse - Disease status: in remission; Other malignant hematologic diseases in remission (to be approved by PI)
• Karnofsky Performance Status ≥ 60% for patients 16 years and older and Lansky Play Score ≥ 60 for patients under 16 years of age (Appendix 1)
• Evaluation of organ status as per MCW BMT SOP
• Infectious disease criteria: No active untreated infection. Patients with possible fungal infections must have had at least 2 weeks of appropriate anti-fungal antibiotics and be asymptomatic
• Signed consent by parent/guardian or able to give consent if ≥18 years
• Negative pregnancy test for patients capable of childbearing potential
• Sexually active patients capable of child-bearing potential must agree to use adequate contraception (diaphragm, birth control pills, injections, intrauterine device [IUD], surgical sterilization, subcutaneous implants, or abstinence, etc.) for the duration of treatment. Sexually active men must agree to use barrier contraceptive for the duration of treatment; Donor Eligibility:
• Unrelated donor meets National Marrow Donor Program criteria for donation
• Infectious disease testing
• MCW BMT procedures apply for determining donor eligibility, including donor screening and testing for relevant communicable disease agents and diseases
• Only Peripheral blood stem cells will be used for stem cell source on this study therefore donor must be willing to undergo G-CSF mobilization and stem cell apheresis. Donor matching. High resolution typing at all loci to be performed
• Unrelated Donor:; HLA typing of at least 10 alleles is required. Donor must be matched at 9/10 or 10/10 alleles (HLA A, B, C, DRB1, DQB1).Donor and collection center willing to undergo mobilization and apheresis
• Haploidentical Related Donor:; Haploidentical parent or other related donor: Minimum match level full haploidentical (at least 5/10; HLA A, B, C, DRB1, DQB1 alleles), but use of haploidentical donors with extra matches (e.g. 6, 7, or 8/10) encouraged

Who cannot take part

• Pregnant or lactating patients are ineligible as many of the medications used in this protocol could be harmful to unborn children and infants
• Receiving concomitant chemotherapy, radiation therapy; immunotherapy or other anti-cancer therapy for treatment of disease other than is specified in the protocol. Maintenance or other post-HCT therapy can be considered after discussion with the study PI
• Participating in a concomitant Phase 1 or 2 study involving treatment of disease
• Patients who do not meet disease, organ, or infectious criteria
• Active malignancy other than eligible disease specified in the protocol. Patients with prior malignancy can be eligible as long as at least 1 year post treatment for that malignancy
• No suitable donor